Objectives: To elucidate clinicopathological risk factors for intravesical recurrence (IVR) in patients undergoing nephroureterectomy for upper urinary tract urothelial carcinoma (UUT-UC). Methods: We identified a study population of 151 consecutive patients without previous or concurrent bladder cancer who underwent nephroureterectomy for UUT-UC. IVR was assessed in relation to tumor location, size, and multifocality, operation modality and time, stage, grade, lymphovascular invasion, regional lymph node metastasis, preoperative urinary cytology, and perioperative chemotherapy. The median follow-up time was 24 months. Results: Of 151 patients, 51 (34%) developed IVR after nephroureterectomy, and 50 (98%) of the patients presented with IVR within 2 years. Tumor multifocality and site (located in ureter) were determined as risk factors for IVR by univariate analysis. In a multivariate analysis, only tumor multifocality (relative risk: 4.024, p = 0.001) was an independent predictor of IVR. Ten-year cancer-specific survival rates for the patients with and without IVR were 68 and 52%, respectively (p = 0.06). Conclusions: Tumor multifocality is a significant risk factor in developing IVR after surgery for UUT-UC. These results indicate that despite most IVR occurring within 2 years of treatment, it is necessary to follow such patients more closely using cystoscopy. However, IVR is unlikely to indicate a poorer prognosis.

Keywords:
Nephroureterectomy, Urothelial carcinoma, Upper urinary tract, Intravesical recurrence, Bladder cancer
1.
Ploeg M, Aben KK, Kiemenery LA: The present and future burden of urinary bladder cancer in the world. World J Urol 2009;27:289–293.
2.
Jema A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics 2009. CA Cancer J Clin 2009;59:225–249.
3.
Walsh PC, Retik AB, Vaughan Jr ED, et al: Campbell’s Urology, ed 9. Philadelphia, Saunders, 2007, p 1638.
4.
Kirkali Z, Tuzel E: Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol 2003;47:155–169.
5.
Hisakata T, Miyao N, Masumori N, Takahashi A, Sasai M, Yanase M, Itoh N, Tsukamoto T: Risk factors for the development of bladder cancer after upper urinary tract urothelial cancer. Urology 2000;55:663–667.
6.
Kang CH, Yu TJ, Hsieh HH, Yang JW, Shu K, Huang CC, Chiang PH, Shiue YL: The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003;98:1620–1626.
7.
Mullerad M, Russo O, Golijanin D, Chen HN, Tsai HH, Donat SM, Bochner BH, Herr HW, Sheinfeld J, Sogani PC, Kattan MW, Dalbagni G: Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma. J Urol 2004;172:2177–2181.
8.
Matsui Y, Utsunomiya N, Ichioka K, Ueda N, Yoshimura K, Terai A, Arai Y: Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 2005;65:279–283.
9.
Raman JD, Ng CK, Boorjian SA, Vaughan Jr ED, Sosa RE, Scherr DS: Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology. BJU Int 2005;96:1031–1035.
10.
Zigeuner RE, Hutterer G, Chromecki T, Rehak P, Langner C: Bladder tumor development after urothelial carcinoma of the upper urinary tract is related to primary tumour location. BJU Int 2006;98:1181–1186.
11.
Koda S, Mita K, Shigeta M, Usui T: Risk factors for intravesical recurrence following urothelial carcinoma of the upper urinary tract: no relationship to the mode of surgery. Jpn J Clin Oncol 2007;37:296–301.
12.
Chung SD, Huang KH, Lai MK, Huang CY, Chen CH, Pu YS, Yu HJ, Chueh SC: CKD as a risk factor for bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Am J Kidney Dis 2007;50:743–753.
13.
Terakawa T, Miyake H, Muramaki M, Takenaka A, Hara I, Fujisawa M: Risk factors for intravesical recurrence after surgical management of the upper urinary tract. Urology 2008;71:123–127.
14.
Li CC, Chang TH, Wu WJ, Ke HL, Huang SP, Tsai PC, Chang SJ, Chen JT, Chou YH, Huang CH: Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol 2008;54:1127–1134.
15.
Huang WW, Huang HY, Liao AC, Shiue YL, Tai HL, Lin CM, Wang YH, Lin CN, Shen KH, Li CF: Primary urothelial carcinoma of the upper tract: important clinicopathological factors predicting bladder recurrence after surgical resection. Pathol Int 2009;59:642–649.
16.
Ku JH, Choi WS, Kwak C, Kim HH: Bladder cancer after nephroureterectomy in patients with urothelial carcinoma of the upper urinary tract. Urol Oncol 2011;29:383–387.
17.
Milojevic B, Djokic M, Sipetic-Grujicic S, Milenkovic-Petronic D, Vuksanovic A, Dragicevic D, Bumbasirevic U, Tulic C: Bladder cancer after managing upper urinary tract transitional cell carcinoma: risk factors and survival. Int Urol Nephrol 2011;43:729–735.
18.
Sobin LH, Witterkind C (eds): TNM Classification of Malignant Tumors, ed 6. New York, Wiley-Liss, 2002.
19.
Lopez-Beltran A, Sauter G, Gasser T, et al: Tumor of the urinary system. Infiltrating urothelial carcinoma; in Eble JN, Sauter G, Epstein JI Sesterhenn IA (eds): World Health Organization Classification of Tumors. Pathology and Genetics. Tumors of the Urinary System and Male Genital Organs. Lyon, IARC Press, 2004, pp 93–109.
20.
Hafner C, Knuechel R, Stoehr R, Hartmann A: Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer 2002;101:1–6.
21.
Takahashi T, Habuchi T, Kakehi Y, Mitsumori K, Akao T, Terachi T, Yoshida O: Clonal and chronological genetic analysis of multifocal cancer of the bladder and upper urinary tract. Cancer Res 1998;58:5835–5841.
22.
Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O: Metachronous multiple development of urothelial cancers by intraluminal seeding. Lancet 1993;342:1087–1088.
23.
Kakizoe T, Fujita J, Murase T, Matsumoto K, Kishi K: Transitional cell carcinoma of the bladder in patients with renal pelvic and ureteral cancer. J Urol 1980;124:17–9.
24.
Akdogan B, Dogan HS, Eskicorapci SY, Sahin A, Erkan I, Ozen H: Prognostic significance of bladder tumor history and tumor location in upper tract transitional cell carcinoma. J Urol 2006;176:48–52.
25.
Sylvester RJ, Oosterlinck W, van der Meijden AP: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta analysis of published results of randomized clinical trials. J Urol 2004;171:2186–2190.
26.
Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, Roupret M, European Association of Urology: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997–1008.
27.
O’Brien T, Ray E, Singh R, Coker B, Beard R: Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomized clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 20011;60:703–710.
28.
Soga N, Arima K, Sugimura Y: Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int J Urol 2008;15:800–803.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.